keyword
MENU ▼
Read by QxMD icon Read
search

R-chop

keyword
https://www.readbyqxmd.com/read/29232438/refractory-or-relapsed-aggressive-b-cell-lymphoma-failing-r-chop-an-analysis-of-patients-treated-on-the-ricover-60-trial
#1
B Glass, A J Dohm, L H Truemper, M Pfreundschuh, A Bleckmann, G G Wulf, A Rosenwald, M Ziepert, N Schmitz
Background: The prognosis of elderly patients with aggressive B-non-Hodgkin's lymphoma after first lymphoma-related treatment failure (TF-L) is not well described. Methods: We analysed patient characteristics including the presence of MYC rearrangements and MYC-expression immunohistochemistry (IHC) at diagnosis and modalities of salvage therapy and their impact on the prognosis of patients between 61 and 80 years who had been treated on the RICOVER-60 trial. Results: TF-L occurred in 301 of the 1222 (24...
December 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29222268/tailoring-front-line-therapy-in-diffuse-large-b-cell-lymphoma-who-should-we-treat-differently
#2
REVIEW
Andrew Davies
Although there have been significant insights into the biology of diffuse large B-cell lymphoma (DLBCL) over recent years, progress in our therapeutic approach has been disappointing over the same timeframe. This is not for want of trying. In 2017, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the "gold standard," despite all of our insights into cell-of-origin and other subgroups. We have traditionally used clinical risk factors to tailor our therapies and have tested intensification of chemotherapy with little success...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29212975/-diffuse-large-b-cell-lymphoma-complicated-with-drug-induced-vasculitis-during-administration-of-pegfilgrastim
#3
Yuta Ito, Kentaro Noda, Keisuke Aiba, Shingo Yano, Tsunehiro Fujii
A 59-year-old female with diffuse large B-cell lymphoma was treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) regimen. In addition, we administered pegfilgrastim for treating chemotherapy-induced febrile neutropenia. She complained of fever and neck and chest pain a few days after pegfilgrastim administration during the third and fourth courses of R-CHOP. Radiological imaging revealed an inflammation of large vessels, which led to the diagnosis of drug-associated vasculitis...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29212973/-refractory-cd20-positive-peripheral-t-cell-lymphoma-showing-loss-of-cd20-expression-after-rituximab-therapy-and-gain-of-cd20-expression-after-administration-of-vorinostat-and-gemcitabine
#4
Kazuaki Teshima, Hideaki Ohyagi, Masaaki Kume, Satsuki Takahashi, Masahiro Saito, Naoto Takahashi
A 79-year-old male patient presented with systemic lymphadenopathy. A lymph node biopsy revealed effacement of the normal nodal architecture with diffuse proliferation of medium-sized atypical lymphoid cells. Southern blot analyses demonstrated rearrangement of the T-cell receptor gene but not the immunoglobulin heavy chain gene. He was diagnosed with CD20-positive peripheral T-cell lymphoma (PTCL), NOS. Although he achieved partial remission after six cycles of R-CHOP, he relapse occurred after 2 months. CD20-negative conversion was confirmed in the lymph node, which was positive for CCR4, and the skin at the time of relapse...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29212420/durable-response-after-vncop-b-and-rituximab-in-an-elderly-patient-with-high-grade-b-cell-lymphoma
#5
Emanuele Cencini, Alberto Fabbri, Luana Schiattone, Francesco Gentili, Maria Antonietta Mazzei, Monica Bocchia
OBJECTIVES AND METHODS:  High-grade B-cell lymphoma, NOS (HGBL) have an aggressive clinical behavior and poor outcome using regimens currently employed for diffuse large B-cell lymphoma (DLBCL) such as rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Promising results have been reported with more intensive regimens but this strategy is not suitable for elderly or unfit patients. Rituximab in association with cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin, and prednisone (R-VNCOP-B) demonstrated high efficacy and manageable toxicity as first-line treatment for elderly aggressive non-Hodgkin lymphoma patients...
December 6, 2017: Acta Clinica Belgica
https://www.readbyqxmd.com/read/29212067/lenalidomide-maintenance-after-r-chop-therapy-in-diffuse-large-b-cell-lymphoma-can-it-be-a-standard-of-care
#6
Reyad Dada
Diffuse large B-cell lymphoma is an aggressive non-Hodgkin lymphoma subtype which requires immediate treatment. Standard treatment is usually a combined immune chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Since R-CHOP was approved, several attempts to combine it with novel agents and/or use them as maintenance therapy failed to improve the outcome. Recently, maintenance with lenalidomide after standard immune chemotherapy showed promising results. This review discusses the most pertinent published and running studies, analyzing study design, results, and practicality...
December 7, 2017: Acta Haematologica
https://www.readbyqxmd.com/read/29208403/efficacy-of-standard-dose-r-chop-alternating-with-r-hdac-followed-by-autologous-hematopoietic-cell-transplantation-as-initial-therapy-of-mantle-cell-lymphoma-a%C3%A2-single-institution-experience
#7
Yazeed Sawalha, Brian T Hill, Lisa A Rybicki, Danyu Sun, Robert M Dean, Deepa Jagadeesh, Betty K Hamilton, Aaron T Gerds, Ronald M Sobecks, Steven Andresen, Hien K Liu, Navneet S Majhail, Brad Pohlman, Matt E Kalaycio, Brian J Bolwell, Mitchell R Smith
BACKGROUND: Young fit patients with mantle cell lymphoma (MCL) are commonly treated with induction chemotherapy followed by high-dose chemotherapy and autologous hematopoietic cell transplantation (AHCT). Induction regimens with modifications of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and/or incorporation of high-dose cytarabine (HDAC) appear more effective than R-CHOP alone. PATIENTS AND METHODS: We adopted a modification of the Nordic protocol using standard, rather than higher dose R-CHOP, alternating with HDAC (rituximab plus HDAC), for 3 cycles each or, for patients already treated with R-CHOP alone before referral for AHCT, an additional 2 cycles of rituximab plus HDAC...
December 2, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29207639/comparative-efficacy-of-different-chemotherapies-for-non-hodgkin-lymphoma-a-network-meta-analysis
#8
Pengcheng Cai, Jinjin Hao, Dan Wang, Jiawei Xu
This network meta-analysis (NMA) was conducted to integrate different chemotherapeutic regimens for non-Hodgkin lymphoma (NHL) patients. Overall survival (OS) and complete remission (CR) were considered as main outcome indicators to evaluate the efficacy of NHL chemotherapies. OS and CR data were extracted from included studies and represented by hazard ratio and odds ratio separately. Network structure and forest plots were further included to visually present the relative efficacy among different regimens...
October 31, 2017: Oncotarget
https://www.readbyqxmd.com/read/29199519/outcomes-of-da-epoch-r-induction-plus-autologous-transplant-consolidation-for-double-hit-lymphoma
#9
Andy I Chen, Jessica T Leonard, Craig Y Okada, Nathan D Gay, Kari Chansky, Guang Fan, Jennifer B Dunlap, Philipp W Raess, Rita M Braziel, Alex Stentz, Richard T Maziarz
High-grade B cell lymphoma with MYC and BCL2 rearrangements (double hit) has a poor prognosis with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). We report here a treatment algorithm of DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) followed by BEAM (carmustine, etoposide, cytarabine, melphalan) autologous transplant in 36 cases of previously untreated double hit lymphoma (DHL) from 2010 to 2015. A high risk International Prognostic Index (IPI) was present in 42% of cases...
December 3, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29196178/long-term-remissions-of-patients-with-follicular-lymphoma-grade-3-treated-with-r-chop
#10
Paolo Strati, Nathan Fowler, Sergio Pina-Oviedo, L Jeffrey Medeiros, Michael J Overman, Jorge E Romaguera, Loretta Nastoupil, Michael Wang, Fredrick B Hagemeister, Alma Rodriguez, Yasuhiro Oki, Jason Westin, Francesco Turturro, Sattva S Neelapu, Luis Fayad
BACKGROUND: The optimal management of patients with follicular lymphoma Grade 3 (FLG3) is controversial. PATIENTS AND METHODS: This is a case series of 45 patients with FLG3 treated with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and observed for an extended time interval. RESULTS: The overall response rate was 100% and the median progression-free survival (PFS) has not been reached, with a 3-year PFS of 70%; 14 (31%) patients relapsed, nearly all within 3 years...
November 14, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29193018/obesity-negatively-impacts-outcome-in-elderly-female-patients-with-aggressive-b-cell-lymphomas-treated-with-r-chop-results-from-prospective-trials-of-the-german-high-grade-non-hodgkin-s-lymphoma-trial-group
#11
K Hohloch, B Altmann, M Pfreundschuh, M Loeffler, N Schmitz, F Zettl, M Ziepert, L Trümper
To study if obesity is a risk factor in elderly patients (>60 years) with aggressive B-cell lymphoma, the outcomes of 576 elderly patients treated with rituximab in the RICOVER-60 trial were analysed in a retrospective study with regard to body mass index (BMI) and gender. Of the 576 patients, 1% had low body weight (BMI < 18·5), 38% were normal weight (18·5 ≤ BMI < 25), 42% were overweight (25 ≤ BMI < 30) and 19% were obese (BMI ≥ 30). Event-free (EFS), progression-free (PFS) and overall survival (OS) according to BMI showed no significant differences for all and for male patients...
November 28, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/29190906/improved-prognostic-stratification-using-nccn-and-geltamo-international-prognostic-index-in-patients-with-diffuse-large-b-cell-lymphoma
#12
Junshik Hong, Seok Jin Kim, Myung Hee Chang, Jeong-A Kim, Jae-Yong Kwak, Jin Seok Kim, Dok Hyun Yoon, Won Sik Lee, Young Rok Do, Hye Jin Kang, Hyeon-Seok Eom, Yong Park, Jong-Ho Won, Yeung-Chul Mun, Hyo Jung Kim, Jung Hye Kwon, Jee Hyun Kong, Sung Yong Oh, Sunah Lee, Sung Hwa Bae, Deok-Hwan Yang, Hyun Jung Jun, Ho Sup Lee, Hwan Jung Yun, Soon Il Lee, Min Kyoung Kim, Jun Ho Yi, Jae Hoon Lee, Won Seog Kim, Cheolwon Suh
The National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) and GELTAMO (Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea)-IPI were developed to enable better risk prediction of patients with diffuse large B-cell lymphoma (DLBCL). The present study compared the effectiveness of risk prediction between IPI, NCCN-IPI, and GELTAMO-IPI in patients with DLBCL particularly in terms of determining high-risk patients. Among 439 patients who were enrolled to a prospective DLBCL cohort treated with R-CHOP immunochemotherapy, risk groups were classified according to the three IPIs and the prognostic significance of individual IPI factors and IPI models were analyzed and compared...
November 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29178090/-treatment-of-primary-gastric-lymphoma
#13
Yi Xia, Zhiwei Zhou
Stomach is the most common location of lymphoma in digestive tract, accounting for 50%-60% of gastrointestinal lymphomas. The most common histological types are low malignant mucosa-associated lymphoid tissue (MALT) lymphoma from non-Hodgkin lymphoma (NHL) and diffuse large B-cell and marginal zone B-cell lymphoma (DLBCL) from NHL. Chronic gastritis secondary to Helicobacter pylori(HP) infection has been considered a major predisposing factor for MALT lymphoma. At present, the most widely accepted initial therapy for localized disease is aimed at the eradication of HP using regimens combining antibiotics and proton-pump inhibitors...
November 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/29151283/clinical-significance-of-rituximab-infusion-related-reaction-in-diffuse-large-b-cell-lymphoma-patients-receiving-r-chop
#14
Kyoung Min Cho, Bhumsuk Keam, Hyerim Ha, Miso Kim, Jae-Woo Jung, Woo-Jung Song, Tae Min Kim, Yoon Kyung Jeon, Hye-Ryun Kang, Dong Wan Kim, Chul Woo Kim, Dae Seog Heo
Background/Aims: This study was to evaluate the clinical significance of infusion-related reaction (IRR) of rituximab in diffuse large B-cell lymphoma (DLBCL) patients who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) as a first-line chemotherapy. Methods: The medical records of 326 patients diagnosed with DLBCL were re trospectively analyzed. Both doctor's progress records and nursing records were reviewed. IRR was graded according to the National Cancer Institute Common Terminology Criteria...
November 20, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29147847/r-hyper-cvad-versus-r-chop-cytarabine-with-high-dose-therapy-and-autologous-haematopoietic-stem-cell-support-in-fit-patients-with-mantle-cell-lymphoma-20%C3%A2-years-of-single-center-experience
#15
Fabienne Widmer, Stefan Balabanov, Davide Soldini, Panagiotis Samaras, Bernhard Gerber, Markus G Manz, Jeroen S Goede
Standard of care for untreated mantle cell lymphoma (MCL) is still debated. At the University Hospital Zurich, advanced MCL in physically fit patients is treated either with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone induction followed by consolidating high-dose chemotherapy and autologous stem cell support (R-CHOP/HD-ASCT), or with rituximab plus fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with high-dose methotrexate-cytarabine (R-hyper-CVAD/MTX-AraC) without consolidating HD-ASCT upon physicians' and patients' choice...
November 16, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29137041/efficacy-of-rituximab-combined-with-chop-for-treating-patients-with-diffuse-large-b-cell-lymphoma
#16
Xin Hu, Min Zeng, Shun-E Yang, Xiao Liang, Shan-Shan Ding, Li Guo, Shan Li, Shu-Juan Wen
BACKGROUND: This study aimed to evaluate the efficacy and safety of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treating patients with diffuse large B-cell lymphoma (DLBCL). METHODS: A total of 144 patients with DLBCL were randomly divided into intervention group and control group, 72 patients in each group. The patients in the control group received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, while the participants in the intervention group received R-CHOP...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29126407/tp53-arg72-as-a-favorable-prognostic-factor-for-chinese-diffuse-large-b-cell-lymphoma-patients-treated-with-chop
#17
Yalu Liu, Xiaogan Wang, Ning Ding, Lan Mi, Lingyan Ping, Xuan Jin, Jiao Li, Yan Xie, Zhitao Ying, Weiping Liu, Chen Zhang, Lijuan Deng, Yuqin Song, Jun Zhu
BACKGROUND: TP53 Arg72Pro (SNP rs1042522) is associated with risk of non-Hodgkin lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL. However, the relationship between this SNP and prognosis of DLBCL in Asians is unknown. METHODS: Genotyping of TP53 Arg72Pro was done in 425 Chinese DLBCL patients. Two hundred and eighty-nine patients were treated with R-CHOP, and 136 patients received CHOP or CHOP-like as frontline regimen. Three hundred and ninety-six patients were assessable for the efficacy...
November 10, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29122756/foxp1-expression-is-a-prognostic-biomarker-in-follicular-lymphoma-treated-with-rituximab-containing-regimens
#18
Anja Mottok, Vindi Jurinovic, Pedro Farinha, Andreas Rosenwald, Ellen Leich, German Ott, Heike Horn, Wolfram Klapper, Michael Boesl, Wolfgang Hiddemann, Christian Steidl, Joseph M Connors, Laurie H Sehn, Randy D Gascoyne, Eva Hoster, Oliver Weigert, Robert Kridel
Follicular lymphoma (FL) is a clinically and molecularly highly heterogeneous disease, yet prognostication relies predominantly on clinical tools. We recently demonstrated that integration of mutation status of seven genes, including EZH2 and MEF2B, improves risk stratification. We mined gene expression data to uncover genes that are differentially expressed in EZH2- and MEF2B-mutated cases. We focused on FOXP1 and assessed its protein expression by immunohistochemistry (IHC) in a total of 763 tissue biopsies...
November 9, 2017: Blood
https://www.readbyqxmd.com/read/29100345/glasgow-prognostic-score-is-superior-to-other-inflammation-based-scores-in-predicting-survival-of-diffuse-large-b-cell-lymphoma
#19
Xiaoxiao Hao, Yongqiang Wei, Xiaolei Wei, Lizhi Zhou, Qi Wei, Yuankun Zhang, Weimin Huang, Ru Feng
Inflammation-based prognostic scores, such as the glasgow prognostic score (GPS), prognostic index (PI), prognostic nutritional index (PNI), neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) were related to survival in many solid tumors. Recent study showed that GPS can be used to predict outcome in diffuse large B-cell lymphoma (DLBCL). However, other inflammation related scores had not been reported and it also remained unknown which of them was the most useful to evaluate the survival in DLBCLs...
September 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/29095677/long-term-results-of-the-foll05-trial-comparing-r-cvp-versus-r-chop-versus-r-fm-for-the-initial-treatment-of-patients-with-advanced-stage-symptomatic-follicular-lymphoma
#20
Stefano Luminari, Angela Ferrari, Martina Manni, Alessandra Dondi, Annalisa Chiarenza, Francesco Merli, Chiara Rusconi, Vittoria Tarantino, Alessandra Tucci, Umberto Vitolo, Sofia Kovalchuk, Emanuele Angelucci, Alessandro Pulsoni, Luca Arcaini, Francesco Angrilli, Gianluca Gaidano, Caterina Stelitano, Giovanni Bertoldero, Nicola Cascavilla, Flavia Salvi, Andrés J M Ferreri, Daniele Vallisa, Luigi Marcheselli, Massimo Federico
Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab plus fludarabine and mitoxantrone) regimens without rituximab maintenance as initial therapy for patients with advanced-stage follicular lymphoma (FL). A previous analysis with a median follow-up of 34 months showed a superior 3-year time to treatment failure, the primary study end point, with R-CHOP and R-FM versus R-CVP and showed R-CHOP to have a better risk-benefit ratio in terms of toxicity than R-FM...
November 2, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
12044
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"